StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about OABI. Only you ever see it.
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $2.01 | $2.19 | +8.96% | 1.1M |
| 05-15 | $2.15 | $2.18 | +1.40% | 0.9M |
| 05-18 | $2.20 | $2.29 | +4.09% | 1.5M |
| 05-19 | $2.29 | $2.37 | +3.49% | 1.2M |
| 05-20 | $2.54 | $2.58 | +1.57% | 1.1M |
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $14.43M | $18.67M | $10.29M | $8.05M |
Operating Income | $-7.83M | $-68.97M | $-53.20M | $-35.06M |
Net Income | $-7.71M | $-64.78M | $-50.60M | $-15.88M |
EPS (Diluted) | $-0.06 | $-0.57 | $-0.46 | $-0.32 |
Total Assets | $293.65M | $300.91M | $309.69M | $295.67M |
Total Liabilities | $31.00M | $33.89M | $32.25M | $33.61M |
Cash & Equivalents | $29.05M | $25.52M | $28.54M | $18.28M |
Free Cash Flow OCF − CapEx | $-5.08M | $-37.02M | $-31.34M | $-21.39M |
Shares Outstanding | 144.78M | 144.31M | 143.96M | 122.70M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.